Athersys Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ATHX Nasdaq 2834 http://www.athersys.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Athersys Inc

Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal - May 23rd, 2022 7:32 pm
Athersys-Partnered Japanese Ischemic Stroke Study Disappoints, Shares Plunge - May 20th, 2022 2:21 pm
Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE MultiStem Ischemic Stroke Study - May 20th, 2022 7:26 am
Athersys to Participate in the H.C. Wainwright Global Investment Conference - May 13th, 2022 12:00 pm
7 Biotech Stocks With Key Catalysts for May - May 11th, 2022 10:35 am
Athersys Reports First Quarter 2022 Results - May 6th, 2022 12:00 pm
Athersys to Participate in the Bank of America Securities 2022 Global Healthcare Conference - May 2nd, 2022 1:00 pm
Athersys to Announce First Quarter Financial Results on May 6 - Apr 29th, 2022 1:00 pm
Athersys closing in on commercialization of its stem cell therapy - Apr 4th, 2022 7:40 pm
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA - Apr 4th, 2022 2:22 pm
Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates on MultiStem® Clinical Programs in Japan - Apr 4th, 2022 10:00 am
Athersys to Participate in Two Upcoming Investor Conferences - Apr 1st, 2022 8:46 pm
Vertex's (VRTX) Pain Candidate Meets Goal in Two Studies - Apr 1st, 2022 4:17 pm
Athersys execs working to address Nasdaq deficiency letter, new CEO says - Apr 1st, 2022 12:40 pm
Blueprint Medicines (BPMC) Gets EU Nod for Ayvakyt in SM - Mar 28th, 2022 4:19 pm
Athersys may be close to commercializing stem cell therapy, new CEO of Cleveland company says - Mar 16th, 2022 10:23 pm
Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why - Mar 16th, 2022 4:00 pm
Athersys Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights - Mar 15th, 2022 8:05 pm
AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal - Mar 15th, 2022 3:35 pm
Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA - Mar 10th, 2022 4:50 pm